Logo_Icesi
 

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

No hay miniatura disponible

Fecha

2014-01-01

Director de tesis/Asesor

Título de la revista

ISSN de la revista

Título del volumen

Publicador

Elsevier

Editor

Compartir

Documentos PDF

Resumen

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment. © 2014 Fabio Bonilla-Abadía et al.

Abstract

Resumo

Descripción

Palabras clave

Lupus eritematoso sistémico, Enfermedad Inflamatoria, Enfermedades autoinmunes

Keywords

Palavras-chave

Citación

DOI

http://dx.doi.org/10.1155/2014/731806

Handle

ISBN

ISSN

0896-8411

OLIB

URL

YouTube

Creative Commons License
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0).